Price increase of 350 drugs in America from the beginning of 2023

According to the report of the International Economy Group of Fars News Agency, citing Reuters, the five largest pharmaceutical companies in the world have decided to increase the prices of 350 special drugs in the United States.

Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca and Sanofi plan to implement these price increases from January 1.

The increases are expected to come as the pharmaceutical industry prepares for the Biden administration’s Inflation Relief Act (IRA). According to this law, the American government’s Medicare health program will be allowed to directly negotiate the price of some drugs from the beginning of 2026.

Currently, the pharmaceutical industry is struggling with inflation and supply chain constraints that have driven up production costs.

This price increase is only in the price list and does not include discounts to pharmacies.

According to statistics from the site “46brooklyn”, pharmacists increased the price of more than 1,400 drugs in 2022, which is the largest increase since 2015.

According to this report, the average increase in drug prices last year was 4.9%.

Probably, the increase in the price of more medicines will be announced in January. Most pharmacists have announced price increases in January.

Until today, by announcing the price increase in 89 specific drug brands, Pfizer has announced the largest price increase, and 10 price increases have been announced in the Hospira brand, which is a subsidiary of this company.

Then there is GSK, which wants to increase the price of 26 specific drugs. Among these drugs, we can mention the shingles vaccine, which is supposed to increase by 7%.

A significant increase in the price of cancer treatment is expected, including a 9% increase in the price of Bristol-Myers Squibb’s CAR-T cell therapies, Abecma and Breyanzi, both of which previously cost more than $400,000 to treat leukemia. They had a cost.

The spokesperson of this company said that several factors, including the inflation rate, the cost of treatments, and the personal nature of the CAR-T production process, are among the reasons for the increase in the price of these two cell treatments.

Pfizer is also raising the cost of Xeljanz, a treatment for autoimmune diseases including rheumatoid arthritis and ulcerative colitis, by 6 percent, and cancer drugs Ibrance and Xalkori by 7.9 percent.

Pfizer’s spokesperson also said that the company’s average price increase for drugs and vaccines in 2023 is lower than the inflation rate and approximately 3.6 percent, which is aimed at supporting the necessary investment in research to find drugs.

AstraZeneca is also going to increase the prices of blood cancer and lung cancer drugs and asthma treatment by 3%.

Sanofi also plans to increase the price of 14 drugs and vaccines.

end of message/